Immutep Ltd. Reg. Sh.(Sp. ADRs II)/10 o.N.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

76.34%

Market Cap

-

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-0.25 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORM
LAST PRICE0.336 G0 Units
PRICE DETERMINATION TIME07/22/2026 / 09:56:59 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW0.3480.328
PREV. DAY'S PRICE0.336 (07/21)
CHANGE DAY BEFORE
+0.00
0.00 %
52 WEEK HIGH / LOW2.74 (01/26)0.246 (04/10)

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-0.28-0.22-0.25-0.23-0.12
DIVIDENDS PER SHARE
0.000.000.00--
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
-----
PRICE - BOOK RATIO
2.782.312.54--
PRICE - SALES RATIO
-----
PRICE - CASH FLOW RATIO
-----
Further Key Figures

Master Data

WKN
A2H8YL
ISIN
US45257L1089
SYMBOL
YP1A
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
IMMUTEP LTD ADRS II/10
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-9.68 %
4.35 %
-31.43 %
-86.34 %
-76.34 %
-82.68 %
-88.87 %
-85.76 %
HIGH0.380.390.492.742.743.024.342.74
LOW0.330.310.300.250.250.250.250.25

Dividende

pro Aktie
IMMUTEP LTD ADRS II/10 does not deliver dividend information

Company profile

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.